Holen Sie sich die Stockscreener-App
27.93
16.68%
-5.59
Schlusskurs vom Vortag:
$33.52
Offen:
$29.66
24-Stunden-Volumen:
13.60M
Relative Volume:
5.36
Marktkapitalisierung:
$5.19B
Einnahmen:
$1.14B
Nettoeinkommen (Verlust:
$-250.98M
KGV:
-20.54
EPS:
-1.36
Netto-Cashflow:
$-251.61M
1W Leistung:
-23.02%
1M Leistung:
+3.52%
6M Leistung:
+31.25%
1J Leistung:
-19.95%
1-Tages-Spanne:
$27.43
$29.80
1-Wochen-Bereich:
$27.43
$36.85
52-Wochen-Spanne:
$16.24
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Firmenname
Legend Biotech Corp Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare LEGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
27.93 | 5.19B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-06-17 | Eingeleitet | Truist | Buy |
| 2024-05-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Buy |
| 2024-04-17 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | Raymond James | Outperform |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-11-06 | Eingeleitet | Goldman | Buy |
| 2023-05-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-05-22 | Eingeleitet | Daiwa Securities | Buy |
| 2023-03-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-11-02 | Eingeleitet | Evercore ISI | Outperform |
| 2022-11-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-03-15 | Eingeleitet | Barclays | Overweight |
| 2022-01-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Why Is Legend Biotech Stock Falling Thursday? - Benzinga
Legend Biotech prices $226 million public offering at $29.35 - Investing.com
Legend Biotech launches $225 million public share offering - Investing.com
Legend Biotech stock falls on $225M share offering plan - Investing.com
Legend Biotech (NASDAQ: LEGN) files $225M ADS offering to fund pipeline - Stock Titan
Legend Biotech stock falls on $225M share offering plan By Investing.com - Investing.com India
Legend Biotech reports early trial success for in vivo CAR-T therapy - Investing.com
UBS raises Legend Biotech stock price target on NHL therapy outlook - Investing.com
GENSCRIPT BIO Spikes 19% as Legend Biotech Corporation (LEGN.US) Announces Positive Prelim Clinical Data for Lymphoma Therapy - aastocks.com
Cancer Drug Proves 100% Successful In Early Study; What's Next? - Investor's Business Daily
Keep an eye on the top gainers and losers in Tuesday's session. - ChartMill
Legend Biotech reports phase 1 data for in vivo CAR-T therapy - Investing.com
金斯瑞生物科技(01548.HK)升19% 傳奇生物(LEGN.US)宣布治療淋巴瘤藥物初步臨床數據現積極信號 - aastocks.com
RBC Capital reiterates Legend Biotech stock rating at Outperform By Investing.com - Investing.com South Africa
RBC Capital reiterates Legend Biotech stock rating at Outperform - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating at buy - Investing.com
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use - Yahoo Finance
H.C. Wainwright reiterates Legend Biotech stock rating at buy By Investing.com - Investing.com South Africa
GENSCRIPT BIO (01548.HK): Legend Biotech Corporation (LEGN.US) Presents Multiple Research Findings at ASCO Annual Meeting in the US - AASTOCKS.com
Earnings call transcript: Legend Biotech reports Q1 2026 loss, stock surges 12% - Investing.com
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals - AOL.com
Legend Biotech stock price target raised to $64 by RBC Capital - Investing.com South Africa
Legend Biotech Q1 2026 slides: strong sales growth, profitability delayed - Investing.com
Earnings call transcript: Legend Biotech’s Q1 2026 earnings miss forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Legend Biotech’s Q1 2026 earnings miss forecasts - Investing.com
Legend Biotech Q1 Earnings Call Highlights - Yahoo Finance
Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short - ChartMill
Legend Biotech stock rises 3% on strong Carvykti sales growth, despite missing estimates By Investing.com - Investing.com South Africa
Legend Biotech stock rises 3% on strong Carvykti sales growth, despite missing estimates - Investing.com
Zurcher Kantonalbank Zurich Cantonalbank Decreases Stake in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech (NASDAQ:LEGN) Stock Price Up 7.7%Time to Buy? - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Investors get Legend Biotech's first-quarter 2026 update on May 12 - Stock Titan
Legend Biotech (LEGN) moves 18.4% higher: Will this strength last? - MSN
Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Lowered by Matthews International Capital Management LLC - MarketBeat
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last? - Yahoo Finance
H.C. Wainwright reiterates Legend Biotech stock rating on M&A activity By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong trial data - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating on M&A activity - Investing.com
Why Legend Biotech Stock Crushed the Market on Monday - AOL.com
RBC Capital reiterates Legend Biotech stock rating on pharma interest By Investing.com - Investing.com India
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday - Benzinga
H.C. Wainwright reiterates Legend Biotech stock rating on pipeline progress - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating on pipeline progress By Investing.com - Investing.com India
HC Wainwright Boosts Earnings Estimates for Legend Biotech - MarketBeat
Finanzdaten der Legend Biotech Corp Adr-Aktie (LEGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):